Amplia Therapeutics Ltd has released a press release.
Capital Raising for Clinical-Enabling Studies
Filed with ASX ·
6ix hasn’t read this filing yet.
Amplia Therapeutics Ltd. on 6ix
Story so far
Earlier from Amplia Therapeutics
- Preliminary Final Report - Year Ended 31 March 2019
- Appendix 4C - Quarterly Statement of Cash Flows
- European Patent Completes IP Protection in Major Markets
- Appendix 4C - December 2018 Quarter Cashflow Statement
- App 4D Half Year Accounts 30 Sep 2018
Later from Amplia Therapeutics
- Dr John Lambert appointed as new CEO
- Rights Issue Prospectus
- Amplia Therapeutics Reports Lead Candidate Preclinical Data
- RightsIssue Participation Supports Clinical-Enabling Studies
- Appendix 4C - Quarterly Cash Flow Report - June 2019 Qtr
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics